Abstract
Abstract
Purpose
Treatment strategies of lymphoid malignancies have been revolutionized by immunotherapy. Because of the inherent property of Hodgkin lymphoma and some subtypes of non-Hodgkin lymphoma as a highly FDG-avid tumor, functional 18F-FDG PET/CT imaging is already embedded in their routine care. Nevertheless, the question is whether it is still valuable in the context of these tumors being treated with immunotherapy. Herein, we will review the value of 18F-FDG PET/CT imaging lymphoid tumors treated with immunotherapy regimens.
Methods
A comprehensive literature search of the PubMed database was conducted on the value of the 18F-FDG PET/CT for immunotherapy response monitoring of patients with malignant lymphoma. The articles were considered eligible if they met all of the following inclusion criteria: (a) clinical studies on patients with different types of malignant lymphoma, (b) treatment with anti-CD20 antibodies, immune checkpoint inhibitors or immune cell therapies, (c) and incorporated PET/CT with 18F-FDG as the PET tracer.
Results
From the initial 1488 papers identified, 91 were ultimately included in our study. In anti-CD20 therapy, the highest pooled hazard ratios (HRs) of baseline, early, and late response monitoring parameters for progression-free survival (PFS) belong to metabolic tumor volume (MTV) (3.19 (95%CI: 2.36–4.30)), maximum standardized uptake value (SUVmax) (3.25 (95%CI: 2.08–5.08)), and Deauville score (DS) (3.73 (95%CI: 2.50–5.56)), respectively. These measurements for overall survival (OS) were MTV (4.39 (95%CI: 2.71–7.08)), DS (3.23 (95%CI: 1.87–5.58)), and DS (3.64 (95%CI: 1.40–9.43)), respectively. Early and late 18F-FDG PET/CT response assessment in immune checkpoint inhibitors (ICI) and immune cell therapy might be an effective tool for prediction of clinical outcome.
Conclusion
For anti-CD20 therapy of lymphoma, the MTV as a baseline 18F-FDG PET/CT-derived parameter has the highest HRs for PFS and OS. The DS as visual criteria in early and late response assessment has higher HRs for PFS and OS compared to the international harmonization project (IHP) visual criteria in anti-CD20 therapy. Early changes in 18F-FDG PET parameters may be predictive of response to ICIs and cell therapy in lymphoma patients.
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine
Reference107 articles.
1. Vassilakopoulos TP, Chatzidimitriou C, Asimakopoulos JV, Arapaki M, Tzoras E, Angelopoulou MK, et al. Immunotherapy in Hodgkin lymphoma: present status and future strategies. Cancers (Basel). 2019;11(8):1071. https://doi.org/10.3390/cancers11081071.
2. Lopci E, Meignan M. Current evidence on PET response assessment to immunotherapy in lymphomas. PET Clin. 2020;15:23–34. https://doi.org/10.1016/j.cpet.2019.08.011.
3. Lin N, Song Y, Zhu J. Immune checkpoint inhibitors in malignant lymphoma: advances and perspectives. Chin J Cancer Res. 2020;32:303–18. https://doi.org/10.21147/j.issn.1000-9604.2020.03.03.
4. Rituximab (marketed as Rituxan) Information. U.S. Food and Drug Administration website. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/rituximab-marketed-rituxan-information. Updated July 23, 2015. Accessed Aug 28, 2021.
5. Obinutuzumab. U.S. Food and Drug Administration website. https://www.fda.gov/drugs/resources-information-approved-drugs/obinutuzumab. Updated Feb 26, 2016. Accessed Aug 28, 2021.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献